Prodrugs of MDMA, MDA, and derivatives thereof
The present disclosure provides prodrug compounds of MDMA, MDA, and derivatives thereof having an improved pharmacokinetic profile suitable for the treatment of various neurological diseases.
1. A compound of Formula (IIIa):
or a pharmaceutically acceptable salt thereof;
wherein,
R 1 is H or alkyl;
R 2 is H, halogen, alkyl, —OH, or —O-alkyl;
R 3 is H, alkyl, —OH, —O-alkyl, or —O-cycloalkyl;
R 4 and R 7 are each independently H, halogen, —OH, —O-alkyl, —O-cycloalkyl, alkylene-OR 8 , —SH, —S-alkyl, —S-cycloalkyl, or alkylene-SR 8 ;
R 8 is H, alkyl, cycloalkyl, or alkylenecycloalkyl;
B is
wherein R B is H or alkyl; and
R 11 and R 12 are each independently H, alkyl, cycloalkyl, or Ru and R 12 together with the atoms to which they are attached form a 5- to 8-membered heterocyclyl ring.
2. The compound of claim 1 , wherein at least one of R 4 and R 7 is not H.
3. The compound of claim 1 , wherein R 1 is H or C 1 -C 6 alkyl.
4. The compound of claim 1 , wherein R 1 is H.
5. The compound of claim 1 , wherein R 1 is —CH 3 .
6. The compound of claim 1 , wherein R 2 is H, alkyl, or —OH.
7. The compound of claim 1 , wherein R 2 is alkyl.
8. The compound of claim 6 , wherein R 2 is methyl or isopropyl.
9. The compound of claim 1 , wherein R 3 is H, —OH, or —O-alkyl.
10. The compound of claim 1 , wherein R 4 is H.
11. The compound of claim 1 , wherein R 7 is H.
12. The compound of claim 1 , having the structure of Formula (IIIb):
or a pharmaceutically acceptable salt thereof,
wherein n is 1 or 2.
13. The compound of claim 12 , having the structure:
or a pharmaceutically acceptable salt thereof.
14. The compound of claim 13 , having the structure:
15. The compound of claim 13 , having the structure:
16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
17. The pharmaceutical composition of claim 16 , wherein the composition provides an in vivo plasma level characterized by a C max of free amine of about 100 ng/mL to about 500 ng/mL, after oral administration of from about 80 mg to about 125 mg of a compound of Formula (IIIa).
18. The pharmaceutical composition of claim 16 , wherein the composition provides an in vivo plasma level characterized by an AUC (0-24) of free amine of about 1000 h*ng/mL to about 6000 h*ng/mL, after oral administration of from about 80 mg to about 125 mg of a compound of Formula (IIIa).
19. The pharmaceutical composition of claim 16 , wherein the composition provides an in vivo T 1/2 of free amine of about 5 h to about 15 h, after oral administration of from about 80 mg to about 125 mg of a compound of Formula (IIIa).
20. A method of treating post-traumatic stress disorder (PTSD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of claim 16 .
21. A method of treating an eating disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of claim 16 .
22. A method of treating depression in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of claim 16 .
23. The method of claim 22 , wherein the depression is major depressive disorder (MDD) or treatment-resistant depression (TRD).
24. A method of treating an anxiety disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of claim 16 .
25. The method of claim 24 , wherein the anxiety disorder is generalized anxiety disorder.